NCT01822431

Brief Summary

This study will examine if one of the following methods: pupillometry, spectral analysis of heart rate variability and metaiodobenzylguanidine scintigraphy, is more capable to detect early diabetic autonomic neuropathy in patients with type 1 diabetes mellitus

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2011

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

March 28, 2013

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 2, 2013

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Last Updated

April 2, 2013

Status Verified

March 1, 2013

Enrollment Period

2 years

First QC Date

March 28, 2013

Last Update Submit

April 1, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • number of participants with abnormal results

    1 day (at time of examination)

Study Arms (2)

Patients with type 1 diabetes mellitus

Metaiodobenzylguanidine scintigraphy, Autonomic function tests, Pupillometry, Holter monitoring

Radiation: metaiodobenzylguanidine scintigraphy

Healthy controls

Autonomic function tests, Pupillometry, Holter monitoring

Interventions

Patients with type 1 diabetes mellitus

Eligibility Criteria

Age20 Years - 49 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients: outpatient diabetes clinic of AHEPA university hospital Controls: residents of Thessaloniki area

You may qualify if:

  • Type 1 diabetes mellitus

You may not qualify if:

  • Type 2 diabetes mellitus
  • Severe cardiac autonomic neuropathy
  • Medications other than insulin
  • Ocular disease other than refractive eye disorders
  • History of neurologic disease
  • History of cardiovascular disease
  • Thyroid disease
  • Vitamin B insufficiency
  • Other possible cause for autonomic failure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AHEPA hospital, First Propedeutic clinic of internal medicine

Thessaloniki, Thessaloniki, 54636, Greece

Location

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

March 28, 2013

First Posted

April 2, 2013

Study Start

June 1, 2011

Primary Completion

June 1, 2013

Last Updated

April 2, 2013

Record last verified: 2013-03

Locations